STAT

FDA urges maker to recall Limbrel after liver and lung injury reports

The FDA asked Primus Pharmaceuticals to recall a product touted as easing osteoarthritis but linked to liver injury and a lung condition.
Source: Andrew Harnik/AP

The Food and Drug Administration has asked Primus Pharmaceuticals to recall a product touted to address “the metabolic processes associated with osteoarthritis” but that the agency says comes

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A GLP-1 Side Effect, U.K. Clinical Trial Transparency, And More
A new study links GLP-1 drugs like Ozempic to a higher risk of aspiration pneumonia — a lung infection caused by food breathed into the lungs — after endoscopies.
STAT1 min read
STAT+: Medicare Expected To Negotiate Obesity Drug Prices Soon, New Analysis Predicts
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An AstraZeneca Deal, A WHO Pandemic Pact, And More
AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on targeted radiation therapies for cancer.

Related